公开(公告)号：US20160313337A1

公开(公告)日：2016-10-27

申请号：US15108283

申请日：2013-12-27

Applicant: KONICA MINOLTA, INC.

Inventor： Katsuko YAMASHITA ,  Takatoshi KAYA ,  Youichi IDE ,  Tomonori KANEKO

IPC: G01N33/574

CPC classification number: G01N33/57434 ,  G01N33/6893 ,  G01N2333/42 ,  G01N2333/4725 ,  G01N2800/342

Abstract: A method of analyzing diagnostic information, the method including: measuring a concentration of a mucin-1 (Tn-MUC1), which is reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine→serine (threonine) residue, in a blood sample originated from a subject to be diagnosed; comparing the measured value with a threshold value; and estimating that a disease affecting the subject to be diagnosed is not prostate cancer but a benign prostate disease when the measured value of the concentration of Tn-MUC1 is greater than the threshold value.

Abstract translation: 一种分析诊断信息的方法，所述方法包括：测量与识别并结合N-乙酰基-D-半乳糖胺→丝氨酸（苏氨酸）残基的凝集素反应的粘蛋白-1（Tn-MUC1）的浓度 来自待诊断对象的血液样本; 将测量值与阈值进行比较; 并且当Tn-MUC1的浓度的测量值大于阈值时，估计影响待诊断对象的疾病不是前列腺癌而是良性前列腺疾病。

公开(公告)号：US20200256796A1

公开(公告)日：2020-08-13

申请号：US16860808

申请日：2020-04-28

Applicant: KONICA MINOLTA, INC.

Inventor： Yukito NAKAMURA ,  Takatoshi KAYA ,  Tomonori KANEKO ,  Kosuke NAGAE ,  Hiroshi HIRAYAMA

IPC: G01N21/64 ,  G01N33/543 ,  G01N21/03

Abstract: A first frame having a first through-hole is arranged on a support so that one opening of the first through-hole is closed. A liquid containing a capturer for capturing a substance to be detected is fed into the first through-hole, and the capturer is immobilized on the support exposed in the first through-hole. After removing the liquid from the support, a second frame having the second through-hole is arranged on the support in the first through-hole so that one opening of the second through-hole is closed.

公开(公告)号：US20190383818A1

公开(公告)日：2019-12-19

申请号：US16464744

申请日：2017-11-29

Applicant: KONICA MINOLTA, INC. ,  HIROSAKI UNIVERSITY

Inventor： Tomonori KANEKO ,  Takatoshi KAYA ,  Chikara OHYAMA ,  Tohru YONEYAMA ,  Yuki TOBISAWA

IPC: G01N33/574 ,  G01N21/64

Abstract: The present invention provides methods that are for acquiring various types of supplementary information used for diagnosis or treatment of prostate cancer, and that can be implemented in a less-invasive manner at a low cost. Provided are, by measuring the content of prostate specific antigen (PSA) having a β-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a specimen, and comparing the measured value with a threshold value, (1) a method for estimating whether a Gleason score (primary pattern and secondary pattern) is not less than or less than a prescribed value, (2) a method for estimating whether the pathological stage (pT) is not less than or less than a prescribed value, and (3) a method for acquiring information for assessment indicating diagnosis or treatment should be actively conducted because a GS at gross total removal is expected to be higher than a GS at biopsy.

公开(公告)号：US20190310257A1

公开(公告)日：2019-10-10

申请号：US16446526

申请日：2019-06-19

Applicant: KONICA MINOLTA, INC.

Inventor： Katsuko YAMASHITA ,  Takatoshi KAYA ,  Youichi IDE ,  Tomonori KANEKO

IPC: G01N33/574 ,  G01N33/68

Abstract: A method of analyzing diagnostic information for estimating which of a benign prostate disease and prostate cancer is affecting a subject to be diagnosed combines two methods of analyzing diagnostic information. The first method includes measuring a concentration of a mucin-1 (Tn-MUC1), reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine->serine(threonine) residue, in a subject blood sample, comparing the measured value with a threshold value, and estimating that a disease affecting the subject is benign prostate disease when the measured value is greater than the threshold value. The second method includes measuring a concentration of a prostate-specific antigen (LacdiNAc-PSA), reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine B1-4 N-acetylglucosamine residue in the blood sample, comparing the measured value with a threshold value, and estimating that the disease affecting the subject is prostate cancer when the measured value of LacdiNAc-PSA is greater than the threshold value.

公开(公告)号：US20180080872A1

公开(公告)日：2018-03-22

申请号：US15558506

申请日：2016-04-05

Applicant: KONICA MINOLTA, INC.

Inventor： Yukito NAKAMURA ,  Takatoshi KAYA ,  Tomonori KANEKO ,  Kosuke NAGAE ,  Hiroshi HIRAYAMA

IPC: G01N21/64 ,  G01N33/543

CPC classification number: G01N21/648 ,  G01N21/03 ,  G01N21/552 ,  G01N21/64 ,  G01N21/6428 ,  G01N33/543 ,  G01N33/54373 ,  G01N2021/6439 ,  G01N2021/6482 ,  G01N2201/0612

Abstract: A first frame having a first through-hole is arranged on a support so that one opening of the first through-hole is closed. A liquid containing a capturer is fed into the first through-hole, and a capturer is immobilized on the support exposed in the first through-hole. After removing the liquid from the support, a second frame having the second through-hole is arranged on the support in the first through-hole so that one opening of the second through-hole is closed.

公开(公告)号：US20210318317A1

公开(公告)日：2021-10-14

申请号：US17272848

申请日：2019-09-25

Applicant: Konica Minolta, Inc.

Inventor： Tomonori KANEKO ,  Takatoshi KAYA ,  Chikara OHYAMA ,  Tohru YONEYAMA ,  Yuki TOBISAWA ,  Osamu OGAWA ,  Takahiro INOUE

IPC: G01N33/574 ,  G16B40/00 ,  G01N21/65

Abstract: The present invention provides a method for acquiring auxiliary information useful to assist a diagnosis or treatment of prostate cancer. The method for acquiring auxiliary information of the present invention is a method for acquiring auxiliary information to assist a diagnosis or treatment of prostate cancer, and includes a step (C) of dividing a concentration value of a prostate specific antigen having a β-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain, contained in a sample derived from a living body, by a volume value of prostate of the living body to calculate the concentration value of the GalNAc-PSA per prostate volume.

公开(公告)号：US20160305960A1

公开(公告)日：2016-10-20

申请号：US15108286

申请日：2013-12-27

Applicant: KONICA MINOLTA, INC.

Inventor： Katsuko YAMASHITA ,  Takatoshi KAYA ,  Youichi IDE ,  Tomonori KANEKO

IPC: G01N33/68 ,  G01N33/573

CPC classification number: G01N33/6893 ,  G01N33/573 ,  G01N33/57434 ,  G01N2333/4725 ,  G01N2333/705 ,  G01N2333/96455 ,  G01N2800/342

Abstract: A method of analyzing diagnostic information, the method including: measuring the concentration of all mucin-1s (total MUC1) in a blood sample originated from a subject to be diagnosed; comparing the measured value with a threshold value; and estimating that a disease affecting the subject to be diagnosed is not prostate cancer but a benign prostate disease when the measured value of the concentration of total MUC1 is greater than the threshold value.

Abstract translation: 一种分析诊断信息的方法，所述方法包括：测量源自待诊断对象的血液样品中所有粘蛋白-1（总MUC1）的浓度; 将测量值与阈值进行比较; 并且当总MUC1的浓度的测量值大于阈值时，估计影响待诊断对象的疾病不是前列腺癌而是良性前列腺疾病。

公开(公告)号：US20200319104A1

公开(公告)日：2020-10-08

申请号：US16754231

申请日：2018-09-20

Applicant: Konica Minolta, Inc.

Inventor： Yukito NAKAMURA ,  Takatoshi KAYA

IPC: G01N21/552 ,  G01N21/64

Abstract: The present invention is to provide a diffracted light removal slit and an optical sample detection system including the same, in which diffracted light of excitation light can be reliably removed without affecting reflected light of the excitation light in a sample detection device utilizing the reflected light of the excitation light. A diffracted light removal slit is provided between a light source unit and an excitation light reflector in an optical sample detection system that emits excitation light from the light source unit and also performs predetermined measurement using reflected light of the excitation light reflected at the excitation light reflector. The diffracted light removal slit includes: a main portion provided in a direction substantially perpendicular to an optical path of the excitation light; and a sidewall portion extending from an end portion of the main portion and inclined toward an upstream side in an optical path direction of the excitation light.

公开(公告)号：US20200150035A1

公开(公告)日：2020-05-14

申请号：US16610707

申请日：2018-04-20

Applicant: Konica Minolta, Inc.

Inventor： Hidetaka NINOMIYA ,  Yukito NAKAMURA ,  Takatoshi KAYA

IPC: G01N21/45 ,  G01B11/06 ,  G01N21/25 ,  G01B11/24

Abstract: A measurement device is for measuring a sample arranged on a thick film transparent medium. In the measurement device, a light projecting surface, a light receiving surface, the thick film transparent medium, and a sample are set so as to satisfy the following formula (α) for eliminating noise light reflected from a back surface of the thick film transparent medium: h

公开(公告)号：US20180348223A1

公开(公告)日：2018-12-06

申请号：US15761637

申请日：2016-09-02

Applicant: KONICA MINOLTA, INC.

Inventor： Tomonori KANEKO ,  Takatoshi KAYA

IPC: G01N33/574

CPC classification number: G01N33/57434 ,  G01N33/53 ,  G01N33/543

Abstract: Provided is a method of obtaining an index value used for pathological tissue diagnosis of prostate cancer, which method has low invasiveness and can be performed at a low cost. The method is a method of estimating a Gleason score that represents the malignancy of prostate cancer, which method includes: measuring the content of a prostate-specific antigen having an N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a sample; and estimating that the Gleason score is 7 or higher when the thus measured value is larger than a threshold value, or estimating that the Gleason score is 6 or lower when the measured value is smaller than a threshold value. The prostate-specific antigen is preferably quantified by a method including the step of binding a molecule having an affinity for β-N-acetylgalactosamine residue, such as Wisteria floribunda lectin, soybean agglutinin, Vicia Villosa lectin or an anti-β-N-acetylgalactosamine antibody, to the prostate-specific antigen.